Bleeding and thrombosis in multiple myeloma and related plasma cell disorders

Seminars in Thrombosis and Hemostasis

Volumn 37, Issue 8, 2011, Pages 929-945

  Coppola, Antonio ^a   Tufano, Antonella ^a   Di Capua, Mirko ^a   Franchini, Massimo ^b  

^a FEDERICO II UNIVERSITY HOSPITAL   (Italy)

^b UNIVERSITY HOSPITAL OF PARMA   (Italy)

Author keywords

Bleeding; hypercoagulability; M protein; multiple myeloma; plasma cell disorders; prophylaxis; thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BORTEZOMIB; DALTEPARIN; DEXAMETHASONE; DOXORUBICIN; ENOXAPARIN; HEMOSTATIC AGENT; IMMUNOGLOBULIN; LENALIDOMIDE; LOW MOLECULAR WEIGHT HEPARIN; MELPHALAN; NADROPARIN; PREDNISONE; THALIDOMIDE; VINCRISTINE; VON WILLEBRAND FACTOR; WARFARIN;

ARTERY THROMBOSIS; ARTICLE; BLEEDING; BLOOD CLOTTING DISORDER; CARDIOVASCULAR RISK; DISEASE CLASSIFICATION; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG WITHDRAWAL; GASTROINTESTINAL HEMORRHAGE; HUMAN; HYPERVISCOSITY SYNDROME; LOW DRUG DOSE; MULTIPLE MYELOMA; MYELOPROLIFERATIVE DISORDER; PATHOPHYSIOLOGY; PLASMA CELL DISORDER; PLASMAPHERESIS; PRIORITY JOURNAL; PROPHYLAXIS; SINGLE DRUG DOSE; THROMBOCYTOPENIA; THROMBOEMBOLISM; THROMBOSIS; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM; VON WILLEBRAND DISEASE;

BLOOD COAGULATION DISORDERS; BLOOD VISCOSITY; HEMORRHAGE; HUMANS; MULTIPLE MYELOMA; THROMBOSIS;

EID: 84555206129     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0031-1297372     Document Type: Article

References (144)

1. Green D. Management of bleeding complications of hematologic malignancies. Semin Thromb Hemost 2007 33 4 427-434 (Pubitemid 46878115)
2. Chong B H., Lee S-H. Management of thromboembolism in hematologic malignancies. Semin Thromb Hemost 2007 33 4 435-448
3. Franchini M, Dario Di Minno M N., Coppola A. Disseminated intravascular coagulation in hematologic malignancies. Semin Thromb Hemost 2010 36 4 388-403
4. Falanga A, Ofosu F A., Delaini F et al. The hypercoagulable state in cancer patients: evidence for impaired thrombin inhibitions. Blood Coagul Fibrinolysis 1994 5 Suppl 1 S19-S23, discussion 5964 (Pubitemid 24049882)
5. Falanga A, Rickles F R. Pathophysiology of the thrombophilic state in the cancer patient. Semin Thromb Hemost 1999 25 2 173-182 (Pubitemid 29227146)
6. Zangari M, Elice F, Fink L, Tricot G. Hemostatic dysfunction in paraproteinemias and amyloidosis. Semin Thromb Hemost 2007 33 4 339-349 (Pubitemid 46878106)
7. Eby C. Pathogenesis and management of bleeding and thrombosis in plasma cell dyscrasias. Br J Haematol 2009 145 2 151-163
8. Zangari M, Anaissie E, Barlogie B et al. Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood 2001 98 5 1614-1615
9. Kyle R A., Gertz M A., Witzig T E. et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 2003 78 1 21-33 (Pubitemid 36033957)
10. Kumar S K., Rajkumar S V., Dispenzieri A et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008 111 5 2516-2520
11. Uaprasert N, Voorhees P M., Mackman N, Key N S. Venous thromboembolism in multiple myeloma: current perspectives in pathogenesis. Eur J Cancer 2010 46 10 1790-1799
12. Zamagni E, Brioli A, Tacchetti P, Zannetti B, Pantani L, Cavo M. Multiple myeloma, venous thromboembolism, and treatment-related risk of thrombosis. Semin Thromb Hemost 2011 37 3 209-219
13. Rajkumar S V., Dispenzieri A, Kyle R A. Monoclonal gammopathy of undetermined significance, Waldenström macroglobulinemia, AL amyloidosis, and related plasma cell disorders: diagnosis and treatment. Mayo Clin Proc 2006 81 5 693-703
14. Kristinsson S Y., Fears T R., Gridley G et al. Deep vein thrombosis after monoclonal gammopathy of undetermined significance and multiple myeloma. Blood 2008 112 9 3582-3586
15. Kyle R A., Rajkumar S V. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia 2009 23 1 3-9
16. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun M J. Cancer statistics, 2009. CA Cancer J Clin 2009 59 4 225-249
17. Perkins H A., MacKenzie M R., Fudenberg H H. Hemostatic defects in dysproteinemias. Blood 1970 35 5 695-707
18. Niléhn J E., Nilsson I M. Coagulation studies in different types of myeloma. Acta Med Scand Suppl 1966 445 194-199
19. Penny R, Castaldi P A., Whitsed H M. Inflammation and haemostasis in paraproteinaemias. Br J Haematol 1971 20 1 35-44
20. Mehta J, Singhal S. Hyperviscosity syndrome in plasma cell dyscrasias. Semin Thromb Hemost 2003 29 5 467-471 (Pubitemid 37352646)
21. Kwaan H C., Bongu A. The hyperviscosity syndromes. Semin Thromb Hemost 1999 25 2 199-208 (Pubitemid 29227148)
22. Crawford J, Cox E B., Cohen H J. Evaluation of hyperviscosity in monoclonal gammopathies. Am J Med 1985 79 1 13-22 (Pubitemid 15072941)
23. Sucker C, Hetzel G R., Grabensee B, Stockschlaeder M, Scharf R E. Amyloidosis and bleeding: pathophysiology, diagnosis, and therapy. Am J Kidney Dis 2006 47 6 947-955 (Pubitemid 43767332)
24. Kyle R A. Multiple myeloma: review of 869 cases. Mayo Clin Proc 1975 50 1 29-40
25. Rossi D, De Paoli L, Franceschetti S et al. Prevalence and clinical characteristics of immune thrombocytopenic purpura in a cohort of monoclonal gammopathy of uncertain significance. Br J Haematol 2007 138 2 249-252 (Pubitemid 46976319)
26. Alpay N, Uzun S, Bahat G, Yavuz S, Erten N, Tascioglu C. Thrombotic thrombocytopenic purpura associated with multiple myeloma. Blood Coagul Fibrinolysis 2008 19 5 439-441
27. Hofmeister C C., Jin M, Cataland S R., Benson D M., Wu H M. TTP disease course is independent of myeloma treatment and response. Am J Hematol 2010 85 4 304-306
28. Sharma P, Kar R, Bhargava R, Ranjan R, Mishra PC, Saxena R. Acquired platelet dysfunction in 109 patients from a tertiary care referral hospital. Clin Appl Thromb Hemost 2011 17 1 88-93
29. DiMinno G, Coraggio F, Cerbone A M. et al. A myeloma paraprotein with specificity for platelet glycoprotein IIIa in a patient with a fatal bleeding disorder. J Clin Invest 1986 77 1 157-164 (Pubitemid 16101214)
30. Ingram G I., Kingston P J., Leslie J, Bowie E J. Four cases of acquired von Willebrand's syndrome. Br J Haematol 1971 21 2 189-199
31. Handin R I., Martin V, Moloney W C. Antibody-induced von Willebrand's disease: a newly defined inhibitor syndrome. Blood 1976 48 3 393-405
32. Federici A B., Budde U, Rand J H. Acquired von Willebrand syndrome 2004: International Registrydiagnosis and management from online to bedside. Hamostaseologie 2004 24 1 50-55 (Pubitemid 38233047)
33. Franchini M, Lippi G. Acquired von Willebrand syndrome: an update. Am J Hematol 2007 82 5 368-375 (Pubitemid 46651140)
34. Tiede A, Priesack J, Werwitzke S et al. Diagnostic workup of patients with acquired von Willebrand syndrome: a retrospective single-centre cohort study. J Thromb Haemost 2008 6 4 569-576 (Pubitemid 351404923)
35. Federici A B. Acquired von Willebrand syndrome: an underdiagnosed and misdiagnosed bleeding complication in patients with lymphoproliferative and myeloproliferative disorders. Semin Hematol 2006 43 1, Suppl 1 S48-S58 (Pubitemid 43150500)
36. Federici A B. Acquired von Willebrand syndrome: is it an extremely rare disorder or do we see only the tip of the iceberg? J Thromb Haemost 2008 6 4 565-568 (Pubitemid 351404922)
37. International Registry on Acquired von Willebrand Syndrome. Available at http://www.intreavws.com Accessed on January 21, 2011
38. Michiels J J., Budde U, van der Planken M, van Vliet H H., Schroyens W, Berneman Z. Acquired von Willebrand syndromes: clinical features, aetiology, pathophysiology, classification and management. Best Pract Res Clin Haematol 2001 14 2 401-436 (Pubitemid 32677087)
39. Scrobohaci M L., Daniel M T., Levy Y, Marolleau J P., Brouet J C. Expression of GpIb on plasma cells in a patient with monoclonal IgG and acquired von Willebrand disease. Br J Haematol 1993 84 3 471-475 (Pubitemid 23224164)
40. Eikenboom J C., van der Meer F J., Briët E. Acquired von Willebrand's disease due to excessive fibrinolysis. Br J Haematol 1992 81 4 618-620
41. Shinagawa A, Kojima H, Berndt M C. et al. Characterization of a myeloma patient with a life-threatening hemorrhagic diathesis: presence of a lambda dimer protein inhibiting shear-induced platelet aggregation by binding to the A1 domain of von Willebrand factor. Thromb Haemost 2005 93 5 889-896 (Pubitemid 40691546)
42. van Genderen P J., Vink T, Michiels J J., van 't Veer M B., Sixma J J., van Vliet H H. Acquired von Willebrand disease caused by an autoantibody selectively inhibiting the binding of von Willebrand factor to collagen. Blood 1994 84 10 3378-3384 (Pubitemid 24352900)
43. Siaka C, Rugeri L, Caron C, Goudemand J. A new ELISA assay for diagnosis of acquired von Willebrand syndrome. Haemophilia 2003 9 3 303-308 (Pubitemid 36622033)
44. Coleman R, Favaloro E J., Soltani S, Keng T B. Acquired von Willebrand disease: potential contribution of the VWF:CB to the identification of functionally inhibiting auto-antibodies to von Willebrand factor. J Thromb Haemost 2006 4 9 2085-2088 (Pubitemid 44226802)
45. Guerin V, Ryman A, Velez F. Acquired von Willebrand disease: potential contribution of the von Willebrand factor collagen-binding to the identification of functionally inhibiting auto-antibodies to von Willebrand factor: a rebuttal. J Thromb Haemost 2008 6 6 1051-1052 (Pubitemid 351689936)
46. Mohri H, Motomura S, Kanamori H et al. Clinical significance of inhibitors in acquired von Willebrand syndrome. Blood 1998 91 10 3623-3629 (Pubitemid 28225728)
47. Teng H W., Chen P M., Yang Y H., Gau J P. The prolonged activated partial thromboplastin time at diagnosis indicates less favorable prognosis in IgA myeloma. Jpn J Clin Oncol 2007 37 8 609-614
48. O'Kane M J., Wisdom G B., Desai Z R., Archbold G P. Inhibition of fibrin monomer polymerisation by myeloma immunoglobulin. J Clin Pathol 1994 47 3 266-268 (Pubitemid 24120693)
49. Kotlín R, Sobotková A, Riedel T et al. Acquired dysfibrinogenemia secondary to multiple myeloma. Acta Haematol 2008 120 2 75-81
50. Glueck H I., Hong R. A circulating anticoagulant in gamma-1A-multiple myeloma: its modification by penicillin. J Clin Invest 1965 44 11 1866-1881
51. Sallah S, Nguyen N P., Abdallah J M., Hanrahan L R. Acquired hemophilia in patients with hematologic malignancies. Arch Pathol Lab Med 2000 124 5 730-734 (Pubitemid 30321878)
52. Franchini M, Targher G, Manzato F, Lippi G. Acquired factor VIII inhibitors in oncohematology: a systematic review. Crit Rev Oncol Hematol 2008 66 3 194-199
53. Sari I, Erkurt M A., Ifran A, Kaptan K, Beyan C. Multiple myeloma presenting with acquired factor VIII inhibitor. Int J Hematol 2009 90 2 166-169
54. Colwell N S., Tollefsen D M., Blinder M A. Identification of a monoclonal thrombin inhibitor associated with multiple myeloma and a severe bleeding disorder. Br J Haematol 1997 97 1 219-226 (Pubitemid 27179591)
55. Holme P A., Brosstad F, Tjønnfjord G E. Acquired haemophilia: management of bleeds and immune therapy to eradicate autoantibodies. Haemophilia 2005 11 5 510-515 (Pubitemid 41283121)
56. Llamas P, Outeiriño J, Espinoza J, Santos A B., Román A, Tomás J F. Report of three cases of circulating heparin-like anticoagulants. Am J Hematol 2001 67 4 256-258 (Pubitemid 32619313)
57. Palmer R N., Rick M E., Rick P D., Zeller J A., Gralnick H R. Circulating heparan sulfate anticoagulant in a patient with a fatal bleeding disorder. N Engl J Med 1984 310 26 1696-1699 (Pubitemid 14124591)
58. Goddard I R., Stewart W K., Hodson B A., Dawes J. Plasma exchange as a treatment for endogenous glycosaminoglycan anticoagulant induced haemorrhage in a patient with myeloma kidney. Nephron 1990 56 1 94-96 (Pubitemid 20226068)
59. Torjemane L, Guermazi S, Ladeb S et al. Heparin-like anticoagulant associated with multiple myeloma and neutralized with protamine sulfate. Blood Coagul Fibrinolysis 2007 18 3 279-281 (Pubitemid 46597402)
60. Yood R A., Skinner M, Rubinow A, Talarico L, Cohen A S. Bleeding manifestations in 100 patients with amyloidosis. JAMA 1983 249 10 1322-1324 (Pubitemid 13147782)
61. Gastineau D A., Gertz M A., Daniels T M., Kyle R A., Bowie E J. Inhibitor of the thrombin time in systemic amyloidosis: a common coagulation abnormality. Blood 1991 77 12 2637-2640
62. Gamba G, Montani N, Anesi E et al. Clotting alterations in primary systemic amyloidosis. Haematologica 2000 85 3 289-292 (Pubitemid 30340146)
63. Mumford A D., O'Donnell J, Gillmore J D., Manning R A., Hawkins P N., Laffan M. Bleeding symptoms and coagulation abnormalities in 337 patients with AL-amyloidosis. Br J Haematol 2000 110 2 454-460 (Pubitemid 30646877)
64. Greipp P R., Kyle R A., Bowie E J. Factor-X deficiency in amyloidosis: a critical review. Am J Hematol 1981 11 4 443-450 (Pubitemid 12248882)
65. Furie B, Greene E, Furie B C. Syndrome of acquired factor X deficiency and systemic amyloidosis in vivo studies of the metabolic fate of factor X. N Engl J Med 1977 297 2 81-85 (Pubitemid 8122843)
66. Sane D C., Pizzo S V., Greenberg C S. Elevated urokinase-type plasminogen activator level and bleeding in amyloidosis: case report and literature review. Am J Hematol 1989 31 1 53-57 (Pubitemid 19127433)
67. Liebman H A., Carfagno M K., Weitz I C. et al. Excessive fibrinolysis in amyloidosis associated with elevated plasma single-chain urokinase. Am J Clin Pathol 1992 98 5 534-541
68. Bouma B, Maas C, Hazenberg B P., Lokhorst H M., Gebbink M F. Increased plasmin-alpha2-antiplasmin levels indicate activation of the fibrinolytic system in systemic amyloidoses. J Thromb Haemost 2007 5 6 1139-1142 (Pubitemid 46902113)
69. Rodrigues C A., Ferrarotto R, Kalil Filho R, Novis YAS, Hoff PMG. Venous thromboembolism and cancer: a systematic review. J Thromb Thrombolysis 2010 30 1 67-78
70. Goldhaber S Z. Risk factors for venous thromboembolism. J Am Coll Cardiol 2010 56 1 1-7
71. Bennet C L., Angelotta C, Yarnold P R. et al. Thalidomide- and lenalinomide-associated thromboembolism among patients with cancer. JAMA 2006 296 21 2558-2560 (Pubitemid 44903859)
72. Bennett C L., Silver S M., Djulbegovic B et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA 2008 299 8 914-924 (Pubitemid 351397066)
73. Katodritou E, Verrou E, Hadjiaggelidou C et al. Erythropoiesis- stimulating agents are associated with reduced survival in patients with multiple myeloma. Am J Hematol 2008 83 9 697-701
74. Bohlius J, Schmidlin K, Brillant C et al. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet 2009 373 9674 1532-1542
75. Srkalovic G, Cameron M G., Rybicki L, Deitcher S R., Kattke-Marchant K, Hussein M A. Monoclonal gammopathy of undetermined significance and multiple myeloma are associated with an increased incidence of venothromboembolic disease. Cancer 2004 101 3 558-566 (Pubitemid 38970607)
76. Sallah S, Husain A, Wan J, Vos P, Nguyen N P. The risk of venous thromboembolic disease in patients with monoclonal gammopathy of undetermined significance. Ann Oncol 2004 15 10 1490-1494 (Pubitemid 39409739)
77. Petropoulou A D., Gerotziafas G T., Samama M M., Hatmi M, Rendu F, Elalamy I. In vitro study of the hypercoagulable state in multiple myeloma patients treated or not with thalidomide. Thromb Res 2008 121 4 493-497 (Pubitemid 351174267)
78. Carr M E. Jr, Dent R M., Carr S L. Abnormal fibrin structure and inhibition of fibrinolysis in patients with multiple myeloma. J Lab Clin Med 1996 128 1 83-88 (Pubitemid 26369173)
79. Yaci M, Sucak G T., Haznedar R. Fibrinolytic activity in multiple myeloma. Am J Hematol 2003 74 4 231-237 (Pubitemid 37484690)
80. Tricot G. New insights into role of microenvironment in multiple myeloma. Lancet 2000 355 9200 248-250 (Pubitemid 30068513)
81. Barillé S, Bataille R, Amiot M. The role of interleukin-6 and interleukin-6/interleukin-6 receptor-alpha complex in the pathogenesis of multiple myeloma. Eur Cytokine Netw 2000 11 4 546-551 (Pubitemid 32044237)
82. Mechtcheriakova D, Wlachos A, Holzmüller H, Binder B R., Hofer E. Vascular endothelial cell growth factor-induced tissue factor expression in endothelial cells is mediated by EGR-1. Blood 1999 93 11 3811-3823 (Pubitemid 29249828)
83. Amrani D L. Regulation of fibrinogen biosynthesis: glucocorticoid and interleukin-6 control. Blood Coagul Fibrinolysis 1990 1 45 443-446
84. Stirling D, Hannant W A., Ludlam C A. Transcriptional activation of the factor VIII gene in liver cell lines by interleukin-6. Thromb Haemost 1998 79 1 74-78 (Pubitemid 28037061)
85. Auwerda JJA, Sonneveld P, de Maat MPM, Leebeek FWG. Prothrombotic coagulation abnormalities in patients with newly diagnosed multiple myeloma. Haematologica 2007 92 2 279-280 (Pubitemid 46852441)
86. van Marion AMW, Auwerda JJA, Lisman T et al. Prospective evaluation of coagulopathy in multiple myeloma patients before, during and after various chemotherapeutic regimens. Leuk Res 2008 32 7 1078-1084
87. Zangari M, Saghafifar F, Anaissie E et al. Activated protein C resistance in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complications. Blood Coagul Fibrinolysis 2002 13 3 187-192 (Pubitemid 35001883)
88. Elice F, Fink L, Tricot G, Barlogie B, Zangari M. Acquired resistance to activated protein C (aAPCR) in multiple myeloma is a transitory abnormality associated with an increased risk of venous thromboembolism. Br J Haematol 2006 134 4 399-405 (Pubitemid 44079553)
89. Gruber A, Blaskó G, Sas G. Functional deficiency of protein C and skin necrosis in multiple myeloma. Thromb Res 1986 42 4 579-581 (Pubitemid 16073480)
90. Deitcher S R., Erban J K., Limentani S A. Acquired free protein S deficiency associated with multiple myeloma: a case report. Am J Hematol 1996 51 4 319-323 (Pubitemid 26116371)
91. Yasin Z, Quick D, Thiagarajan P, Spoor D, Caraveo J, Palascak J. Light-chain paraproteins with lupus anticoagulant activity. Am J Hematol 1999 62 2 99-102 (Pubitemid 29463721)
92. Bellotti V, Gamba G, Merlini G et al. Study of three patients with monoclonal gammopathies and lupus-like anticoagulants. Br J Haematol 1989 73 2 221-227 (Pubitemid 19256116)
93. Takamiya O, Machida S, Okuda M, Nojima J, Koreeda C, Kubara K. A non-immunological phospholipid-dependent coagulation inhibitor associated with IgGlambda-type multiple myeloma. Am J Hematol 2004 75 1 34-39 (Pubitemid 38040165)
94. Swystun L L., Shin L Y., Beaudin S, Liaw P C. Chemotherapeutic agents doxorubicin and epirubicin induce a procoagulant phenotype on endothelial cells and blood monocytes. J Thromb Haemost 2009 7 4 619-626
95. Reddy K V., Bhattacharjee G, Schabbauer G et al. Dexamethasone enhances LPS induction of tissue factor expression in human monocytic cells by increasing tissue factor mRNA stability. J Leukoc Biol 2004 76 1 145-151 (Pubitemid 38857181)
96. Kerachian M A., Cournoyer D, Harvey E J. et al. Effect of high-dose dexamethasone on endothelial haemostatic gene expression and neutrophil adhesion. J Steroid Biochem Mol Biol 2009 116 35 127-133
97. van Giezen J J., Jansen J W. Correlation of in vitro and in vivo decreased fibrinolytic activity caused by dexamethasone. Ann N Y Acad Sci 1992 667 199-201 (Pubitemid 23061582)
98. Arkel Y S., Ku D H., Thurston A L. The effect of thalidomide on tissue factor activity in Mono Mac 6 cells and the relationship to tumor necrosis factor (TNF)-alpha-stimulated cells. J Thromb Haemost 2003 1 12 2691-2692
99. Zangari M, Guerrero J, Cavallo F, Prasad H K., Esseltine D, Fink L. Hemostatic effects of bortezomib treatment in patients with relapsed or refractory multiple myeloma. Haematologica 2008 93 6 953-954 (Pubitemid 351821742)
100. Hiroi T, Deming C B., Zhao H et al. Proteasome inhibitors enhance endothelial thrombomodulin expression via induction of Krüppel-like transcription factors. Arterioscler Thromb Vasc Biol 2009 29 10 1587-1593
101. Ghosh N, Ye X, Ferguson A, Huff C A., Borrello I. Bortezomib and thalidomide, a steroid free regimen in newly diagnosed patients with multiple myeloma. Br J Haematol 2011 152 5 593-599
102. Lackner H. Hemostatic abnormalities associated with dysproteinemias. Semin Hematol 1973 10 2 125-133
103. Glaspy J A. Hemostatic abnormalities in multiple myeloma and related disorders. Hematol Oncol Clin North Am 1992 6 6 1301-1314
104. Talamo G, Farooq U, Zangari M et al. Beyond the CRAB symptoms: a study of presenting clinical manifestations of multiple myeloma. Clin Lymphoma Myeloma Leuk 2010 10 6 464-468
105. Kyrtsonis M C., Vassilakopoulos T P., Angelopoulou M K. et al. Waldenström's macroglobulinemia: clinical course and prognostic factors in 60 patients. Experience from a single hematology unit. Ann Hematol 2001 80 12 722-727
106. Kyle R A., Gertz M A. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol 1995 32 1 45-59 (Pubitemid 24370135)
107. Ebert E C., Nagar M. Gastrointestinal manifestations of amyloidosis. Am J Gastroenterol 2008 103 3 776-787 (Pubitemid 351405997)
108. Kim S H., Kang E J., Park J W. et al. Gastrointestinal amyloidosis presenting with multiple episodes of gastrointestinal bleeding. Cardiovasc Intervent Radiol 2009 32 3 577-580
109. Oluk M A., Murphy J. Nasopharyngeal amyloidosis: an unusual cause for epistaxis. J Laryngol Otol 2010 124 2 209-212
110. Morita Y, Yasuda M, Nakao M, Tsujimura Y, Isono M. Pulmonary hemorrhage and acute renal failure as an initial presentation of multiple myeloma. Intern Med 2010 49 14 1401-1403
111. Crowley R W., Sansur C A., Sheehan J P., Mandell J W., Kassell N F., Dumont A S. Intracranial plasmacytoma with apoplectic presentation and spontaneous intracerebral hemorrhage: Case report and review of the literature. Clin Neurol Neurosurg 2010 112 2 172-175
112. Oshima K, Kanda Y, Nannya Y et al. Clinical and pathologic findings in 52 consecutively autopsied cases with multiple myeloma. Am J Hematol 2001 67 1 1-5 (Pubitemid 32336696)
113. Franchini M, Lippi G. Acquired factor VIII inhibitors. Blood 2008 112 2 250-255
114. Collins P, Budde U, Rand J H., Federici A B., Kessler C M. Epidemiology and general guidelines of the management of acquired haemophilia and von Willebrand syndrome. Haemophilia 2008 14 Suppl 3 49-55 (Pubitemid 351722383)
115. Franchini M. The use of recombinant activated factor VII in platelet disorders: a critical review of the literature. Blood Transfus 2009 7 1 24-28
116. De Simone C, Catalano L, Coppola A et al. Acquired hemophilia: an early marker of relapse in a patient with a history of multiple myeloma. Haematologica 2004 89 Suppl 8 145
117. Boggio L, Green D. Recombinant human factor VIIa in the management of amyloid-associated factor X deficiency. Br J Haematol 2001 112 4 1074-1075 (Pubitemid 32322939)
118. Mannucci P M., Levi M. Prevention and treatment of major blood loss. N Engl J Med 2007 356 22 2301-2311 (Pubitemid 46849160)
119. Friederich P W., Wever P C., Briët E, Doorenbos C J., Levi M. Successful treatment with recombinant factor VIIa of therapy-resistant severe bleeding in a patient with acquired von Willebrand disease. Am J Hematol 2001 66 4 292-294 (Pubitemid 32210299)
120. Smaradottir A, Bona R. A case of acquired von Willebrand syndrome successfully treated with recombinant Factor VIIa during thyroidectomy. Thromb Haemost 2004 92 5 666-667 Correction in Thromb Haemost 2005; 93(5):1009 (Pubitemid 39248026)
121. Federici A B., Stabile F, Castaman G, Canciani M T., Mannucci P M. Treatment of acquired von Willebrand syndrome in patients with monoclonal gammopathy of uncertain significance: comparison of three different therapeutic approaches. Blood 1998 92 8 2707-2711 (Pubitemid 28469082)
122. Thompson C A., Kyle R, Gertz M, Heit J, Pruthi R, Pardanani A. Systemic AL amyloidosis with acquired factor X deficiency: A study of perioperative bleeding risk and treatment outcomes in 60 patients. Am J Hematol 2010 85 3 171-173
123. Zangari M, Tricot G, Polavaram L et al. Survival effect of venous thromboembolism in patients with multiple myeloma treated with lenalidomide and high-dose dexamethasone. J Clin Oncol 2010 28 1 132-135
124. Carrier M, Le Gal G, Tay J, Wu C, Lee A Y. Rates of venous thromboembolism in multiple myeloma patients undergoing immunomodulatory therapy with thalidomide or lenalidomide: a systematic review and meta-analysis. J Thromb Haemost 2011 9 4 653-663
125. Verheul HMW, Pinedo H M. Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition. Nat Rev Cancer 2007 7 6 475-485 (Pubitemid 46809172)
126. Jagannath S, Barlogie B, Berenson J R. et al, SUMMIT/CREST Investigators. Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impared renal function. Cancer 2005 103 6 1195-1200 (Pubitemid 40328090)
127. Raven W, Berghout A, van Houten A, Leebeek F W. Treatment of multiple myeloma and arterial thrombosis. Ann Hematol 2010 89 4 419-420
128. Libourel E J., Sonneveld P, van der Holt B, de Maat MPM, Leebeek FWG. High incidence of arterial thrombosis in young patients treated for multiple myeloma: results of a prospective cohort study. Blood 2010 116 1 22-26
129. Geerts W H., Bergqvist D, Pineo G F. et al, American College of Chest Physicians. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008 133 6, Suppl 381S-453S (Pubitemid 351894916)
130. Palumbo A, Rajkumar S V., Dimopoulos M A. et al, International Myeloma Working Group. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia 2008 22 2 414-423 (Pubitemid 351255436)
131. Musallam K M., Dahdaleh F S., Shamseddine A I., Taher A T. Incidence and prophylaxis of venous thromboembolic events in multiple myeloma patients receiving immunomodulatory therapy. Thromb Res 2009 123 5 679-686
132. Palumbo A, Davies F, Kropff M et al. Consensus guidelines for the optimal management of adverse events in newly diagnosed, transplant-ineligible patients receiving melphalan and prednisone in combination with thalidomide (MPT) for the treatment of multiple myeloma. Ann Hematol 2010 89 8 803-811
133. Barlogie B, Tricot G, Anaissie E et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med 2006 354 10 1021-1030 (Pubitemid 43357806)
134. Zangari M, Barlogie B, Anaissie E et al. Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation. Br J Haematol 2004 126 5 715-721 (Pubitemid 39221309)
135. Palumbo A, Bringhen S, Caravita T et al, Italian Multiple Myeloma Network, GIMEMA. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 2006 367 9513 825-831 (Pubitemid 43363369)
136. Minnema M C., Breitkreutz I, Auwerda J J. et al. Prevention of venous thromboembolism with low molecular-weight heparin in patients with multiple myeloma treated with thalidomide and chemotherapy. Leukemia 2004 18 12 2044-2046 (Pubitemid 40028434)
137. Wang M, Weber D M., Delasalle K, Alexanian R. Thalidomide-dexamethasone as primary therapy for advanced multiple myeloma. Am J Hematol 2005 79 3 194-197 (Pubitemid 40967073)
138. Weber D, Rankin K, Gavino M, Delasalle K, Alexanian R. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol 2003 21 1 16-19
139. Cavo M, Zamagni E, Tosi P et al, Bologna 2002 study. Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood 2005 106 1 35-39 (Pubitemid 40967171)
140. Klein U, Kosely F, Hillengass J et al. Effective prophylaxis of thromboembolic complications with low molecular weight heparin in relapsed multiple myeloma patients treated with lenalidomide and dexamethasone. Ann Hematol 2009 88 1 67-71
141. Knop S, Gerecke C, Liebisch P et al. Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom). Blood 2009 113 18 4137-4143
142. Baz R, Li L, Kottke-Marchant K et al. The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma. Mayo Clin Proc 2005 80 12 1568-1574 (Pubitemid 41747058)
143. Rajkumar S V., Hayman S R., Lacy M Q. et al. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood 2005 106 13 4050-4053 (Pubitemid 41775908)
144. Palumbo A, Falco P, Corradini P et al, GIMEMAItalian Multiple Myeloma Network. Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMAItalian Multiple Myeloma Network. J Clin Oncol 2007 25 28 4459-4465 (Pubitemid 350063804)